Revenue reaches record high with EBITDA positive

• Net sales amounted to 21.5 MSEK (15.9), an increase of 35 percent over the same period in 2022.
• Operating result amounted to -3.5 MSEK (-6.1).
• Net result after financial items amounted to -3.9 MSEK (-6.5).
•  Earnings per share were -0.06 SEK (-0.10).
• Cash Balance amounted to 11.7 MSEK (11.3).
• Average Daily Treatment Revenue (ADTR)* was 242 TSEK (179), an increase of 35 percent over the same period in 2022.
• EBITDA positive for the period.

• In March Dignitana AB signed Science International Corporation, a leading distributor for medical devices, to launch The DigniCap Scalp Cooling System in Hong Kong and Macao.
• In the first period Dignitana exhibited at two conferences, Onkologidagarna in Sweden and National Consortium of Breast Centers in the US, where a session on DigniCap was also presented by a customer.
• Dignitana's prominent visibility in the breast cancer community continued with the Susan G. Komen® More Than Pink Walk in West Palm Beach, Florida in January.

• Dignitana exhibited at the Oncology Nursing Congress in San Antonio, Texas.

Key Figures

DIGNITANA GROUP Q1 2023 Q1 2022 Full year 2022
Net sales, TSEK 21,489 15,864 72,995
Total revenues, TSEK 21,605 16,710 83,849
Net profit after -3,938 -6,508 -22,396
financial items, TSEK
Cash and bank balances, 11,726 11,311 8,869
TSEK
Earnings per share -0.06 -0.10 -0.34
before and after
dilution, SEK
Average Daily Treatment 242 179 203
revenue*, TSEK

*ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

"The evidence of DigniCap Delta's efficacy, ease of use and patient happiness are supported by extraordinary customer satisfaction and a patient recommendation score of 97 percent." - Catarina Löwenadler, CEO Dignitana AB

All financial reports are available at www.dignitana.com/investor-relations/financial-reports/

This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-05-2023 08:00 CET.